Dr Pai's venture firm Aarin Capital is an investor in Vyome
Vyome Biosciences has announced that MD and CEO of Manipal Education and Medical Group, Dr Ranjan Pai, has joined its board of directors. Dr Pai's venture firm Aarin Capital is an investor in Vyome.
The company also appointed Dr Richard Buchta, formerly Head of GlaxoSmithKline's dermatology unit Stiefel Laboratories in Australia, as senior vice-president, R&D.
"Dr Pai is recognised as one of India's top corporate leaders. As Vyome scales operations and prepares to enter the commercialisation phase, his addition adds tremendous strategic experience to the Board. The globalisation and expansion of the Manipal Education and Medical Group through his strategic vision is an experience that will serve Vyome in good stead as the company looks abroad for development and licensing opportunities," said Mr N Venkat, co-founder and CEO, Vyome Biosciences.
"Vyome is a proving to be a serious innovative play in the lifesciences industry, and holds a special place in Aarin's portfolio. I am personally looking forward to work more closely with the rest of the board, Shiladitya, Venkat and the rest of their team as the company breaks new ground in markets both in India and abroad," said Dr Pai.
"Dr Buchta brings rich specialist experience with numerous patent applications and multiple IND filings in dermatology to Vyome's senior management team, and this will multiply the Company's capabilities as we enter the regulatory filing stages for our pharmaceutical programs. Vyome is geared up to press ahead on," added Mr Venkat.
